Home/ Stocks/ IMUX

Immunic, Inc. Common Stock

IMUX XNAS

$14.30 -0.24 (-1.65%) ▼ 15-min delayed

Open

$14.68

High

$15.63

Low

$14.27

Volume

175.5K

Market Cap

$198.06M

About Immunic, Inc. Common Stock

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 95 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-32,588,000	$-1.08
FY 2025	$0	$-97,172,000	$-0.62
Q3 2025	$0	$-25,579,000	$-0.13
Q2 2025	$0	$-26,820,000	$-0.20

Related Market News

No specific coverage for IMUX yet. Check out our latest market news or earnings calendar.

Get IMUX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Immunic, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.